Mismatch repair (MMR) is an essential process that maintains genome integrity. The likelihood of replication errors in newly synthesized DNA is dramatically decreased by the action of a highly conserved MMR system. Mismatches are recognized by one of two heterodimers, MSH2 Á MSH6 (MutSa) or MSH2 Á MSH3 (MutSb) , that are believed to travel with the replication fork. MutSa is involved in the repair of base/base mismatches and misalignments of one or two nucleotides, while the less abundant MutSb recognizes larger mismatches. MutSa (or MutSb) recruits a second heterodimer, MLH1 Á PMS2 (referred to as MutLa), that possesses a probable endonuclease active site, which has been localized to a PMS2 DQHA(X) 2-E(X) 4 E motif. This endonuclease active site enables MutLa to introduce random nicks at sites spanning the mismatch. Subsequent loading of EXO1 at the 5 0 side of the mismatch leads to activation of its 5 0 -to-3 0 exonuclease activity, resulting in removal of the error-containing DNA fragment. The reparation process is completed by polymerase d and its cofactors, proliferation cell nuclear antigen and replication factor C that fill in the single-stranded gap. Finally, ligase I seals the remaining nick (Figure 1 ; reviewed in Jiricny 1 ). In addition to DNA repair activity, the MMR system is also involved in apoptotic response to a variety of DNA damaging agents (reviewed in Jiricny 2 ). Heterozygous germline loss-of-function mutations of the genes encoding the crucial components of this MMR system, MLH1, MSH2, MSH6 or PMS2, cause Lynch syndrome, a wellcharacterized dominant cancer syndrome associated with hereditary non-polyposis colorectal cancer, and other malignancies (reviewed in Peltomaki 3 ). Tumors arising in these individuals result from somatic loss of the remaining wild type MLH1, MSH2, MSH6 or PMS2 allele, which leads to impaired MMR and accumulation of somatic mutations.
In contrast to individuals with Lynch syndrome who harbor a heterozygous mutant MMR gene allele, rare cases with biallelic germline mutations have been reported. Biallelic mutations of MLH1, MSH2, MSH6 or PMS2 cause a recessive childhood cancer syndrome characterized by café-au-lait spots and other signs of neurofibromatosis type 1, childhood brain tumors, leukemia, lymphoma, colorectal cancer and other malignancies (reviewed in Felton et al. 4 ). This syndrome is referred to as childhood cancer syndrome, 5 mismatch repair deficiency (MMR-D) syndrome 6 or Lynch III syndrome. 7 To date, 14 families with a biallelic PMS2 lesion have been described, 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and PMS2 deficient mice have been shown to be at high tumor (mainly lymphoma) risk. 18 Herein, we report on a 6-year-old Turkish girl with multiple café-au-lait spots presenting with severe respiratory distress. Radiologic examination revealed a large mediastinal mass, pleural effusions and bilateral infiltration of both kidneys. The diagnosis of T-cell lymphoblastic lymphoma was established by morphologic examination of pleural fluid showing lymphoblasts and flow cytometry revealing 490% of cells positive for CD2, CD3, CD5, CD7, CD8 and TdT with coexpression of CD13. Cytogenetic analysis of these cells showed a normal karyotype. Analyses of bone marrow cells did not uncover blast infiltration.
The patient was successfully treated according to the NHL-BFM 95 protocol and remained in remission for 10 years. At the age of 16 years she presented with weight and hair loss, abdominal pain and amenorrhea. Blood tests showed iron and zinc deficiency. Imaging studies revealed large colonic tumors. Histologic examination of a biopsy taken on colonoscopy uncovered the diagnosis of colorectal carcinomas originating from adenomatosis. Subsequently, colectomy was performed and pathological analyses revealed adenomatosis polyposis and multiple colon carcinomas. Metastases were found in 3 out of 97 lymph nodes examined. The patient is currently recovering from her colectomy, which was complicated by several infectious episodes.
Family history is remarkable for one sister with café-au-lait spots who died from a supratentorial primitive neuroectodermal tumor at the age of 9 years. Both parents had no history of cancer. Four siblings were healthy at the time of this report. Because this case resembled previous cases of MMR-D syndrome, further analyses were performed. Notably, supratentorial primitive neuroectodermal tumors have thus far been reported only in MMR-D syndrome patients with biallelic PMS2 defects. 10 Employing markers BAT-25, BAT-26, NR-21, NR-24 and MONO-27 (Promega Corp., Madison, WI, USA), microsatellite analysis of colon carcinoma cells revealed instability of five markers tested. Staining with antibodies directed against MLH1, MSH2, MSH6 and PMS2 revealed absence of PMS2 expression. Subsequent PMS2 mutational analysis employing a new RNA-based method 16 that circumvents pseudogene interference revealed a novel homozygous frameshift mutation of PMS2 exon 11, c.1306dupA, leading to a premature stop codon (p.Ser436LysfsX22). This finding was confirmed by sequencing of genomic DNA from this individual and is consistent with the diagnosis of MMR-D syndrome due to a homozygous PMS2 mutation. As expected, both parents were heterozygous carriers of the mutant PMS2 allele. Mutation analysis of DNA from the remaining siblings, one of whom has café-au-lait spots, is pending. The absence of malignancies in the heterozygous parents is not surprising, as heterozygous PMS2 mutations are known to have a low penetrance (reviewed in Truninger et al.
19
). The recognition of this MMR-D syndrome has scientific and clinical implications: (1) impaired MMR may play a yet underestimated role in the pathogenesis of sporadic cancers such as leukemia/lymphoma and brain tumors, which deserve further investigation; (2) Figure 1 Simplified model of the mismatch repair system (for a more comprehensive review see refs. 1, 2 ). Recently, the Intergroupe Francophone du Mye'lome (IFM) published their data on the impact of genetics on survival in a large cohort of newly diagnosed patients treated with high-dose melphalan and stem cell transplantation (HDT). They showed that t(4;14) and 17p13 deletion are powerful independent prognostic factors in patients with either of these abnormalities identifying a group of patients with the worst prognosis. However, among these patients, those with b2 microglobulin (B2M) 44 mg l À1 have significantly shorter survival (median survival of about 20 months).
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1 B2M level of 44 was also an independent prognostic factor among 100 patients with t(4;14) treated with tandem stem cell transplantation on IFM trials. 2 We have previously also shown that t(4;14) and 17p13 deletion are independent prognostic factors in newly diagnosed patients entered into Eastern Cooperative Oncology Group (ECOG) E9486/E9487 clinical trials 3 using melphalan-based chemotherapy. With a much longer median follow-up of 12 years now for surviving patients in the whole trial cohort, we confirmed that the presence of t(4;14) or 17p13 (n ¼ 71) is significantly associated with shorter survival compared to those without (n ¼ 258) (median survival of 25.1 compared to 47.4 months, log-rank P-value o0.0001). We then analyzed the impact of different B2M cut-off levels on the survival of these high-risk patients. Using cutoffs of 3.5 mg l À1 , 4 mg l À1 (used by the IFM) 1 and 5.5 mg l À1 (used to define ISS stage III), 4 we found that the survival of patients with t(4;14) and/or 17p13 deletion are not affected by any of these B2M levels (Figure 1) . Similarly, these B2M levels do not effect progression-free survival (PFS) in our data set (Figure 2 ), whereas B2M 4 4 mg l À1 is significantly associated with shorter PFS in the IFM study.
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Figure 1
Overall survival of patients with t(4;14) and/or 17p13 deletion according to b2 microglobulin (B2M) levels. Survival of these patients was not affected by B2M levels using different cut-off levels of (a) 3.5 mg l À1 , (b) 4 mg l À1 and (c) 5.5 mg l
À1
. Survival times are in months.
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